Judicious use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes on coronavirus-19 pandemic

Sodium glucose cotransporter-2 inhibitors (SGLT2i), a novel antidiabetic drug blocks the reabsorption of glucose in proximal tubules of kidney, are demonstrated to have cardiovascular and renal benefits for people with diabetes. The benefits are associated with the significant increase of intrarenal...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chun-Fan, Chen, Yung-Tai, Chen, Tz-Heng, Chen, Fan-Yu, Yang, Yi-Ping, Wang, Mong-Lien, Huo, Teh-Ia, Chang, Yuh-Lih, Charis Tan, Ann, Lin, Chih-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434023/
https://www.ncbi.nlm.nih.gov/pubmed/32433344
http://dx.doi.org/10.1097/JCMA.0000000000000354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434023/
https://www.ncbi.nlm.nih.gov/pubmed/32433344
http://dx.doi.org/10.1097/JCMA.0000000000000354

Ejemplares similares